Increasing burden of liver disease in patients with HIV infection

The Lancet

Volumn 377, Issue 9772, 2011, Pages 1198-1209

  Joshi, Deepak ^a   O'Grady, John ^a   Dieterich, Doug ^b   Gazzard, Brian ^c   Agarwal, Kosh ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b MOUNT SINAI HOSPITAL   (United States)

^c CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; HEPATITIS B; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER CELL CARCINOMA; LIVER DISEASE; LIVER TOXICITY; LIVER TRANSPLANTATION; MORBIDITY; MORTALITY; NONALCOHOLIC FATTY LIVER; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SUPERINFECTION;

EID: 79953285141     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(10)62001-6     Document Type: Review

References (129)

1. Joint UN Programme on HIV/AIDS 2006 report on the global AIDS epidemic: a UNAIDS 10th anniversary special edition. Executive summary http://data.unaids. org/pub/GlobalReport/2006/2006-gr-executivesummary-en.pdf (accessed Feb 9, 2010).
2. A Mocroft, R Brettle, O Kirk Changes in the cause of death among HIV positive subjects across Europe: results from the EuroSIDA study AIDS 16 2002 1663 1671 (Pubitemid 34921112)
3. R Weber, CA Sabin, N Friis-Moller Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study Arch Intern Med 166 2006 1632 1641 (Pubitemid 44232373)
4. D Salmon-Ceron, C Lewden, P Morlat Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol J Hepatol 42 2005 799 805 (Pubitemid 40693195)
5. MJ Koziel, MG Peters Viral hepatitis in HIV infection N Engl J Med 356 2007 1445 1454 (Pubitemid 46556329)
6. Y Benhamou, M Bochet, V Di Martino for the Multivirc Group Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients Hepatology 30 1999 1054 1058 (Pubitemid 29458296)
7. JA Pineda, M Romero-Gomez, F Diaz-Garcia HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis Hepatology 41 2005 779 789 (Pubitemid 40462940)
8. JA Pineda, JA Garcia-Garcia, M Aguilar-Guisado Clinical progression of hepatitis C virus-related chronic liver disease in human immunodeficiency virus-infected patients undergoing highly active antiretroviral therapy Hepatology 46 2007 622 630 (Pubitemid 47436106)
9. PS Kamath, WR Kim The model for end-stage liver disease (MELD) Hepatology 45 2007 797 805 (Pubitemid 46450631)
10. A Subramanian, M Sulkowski, B Barin MELD score is an important predictor of pretransplantation mortality in HIV-infected liver transplant candidates Gastroenterology 138 2010 159 164
11. Murillas J, Rimola A, Laguno M, et al. The model for end-stage liver disease score is the best prognostic factor in human immunodeficiency virus 1-infected patients with end-stage liver disease: a prospective cohort study. Liver Transpl; 15: 1133-41.
12. P Tuma, I Jarrin, AJ Del Survival of HIV-infected patients with compensated liver cirrhosis AIDS 24 2010 745 753
13. E Rosenthal, G Pialoux, N Bernard Liver-related mortality in human-immunodeficiency-virus-infected patients between 1995 and 2003 in the French GERMIVIC Joint Study Group Network (MORTAVIC 2003 study) J Viral Hepat 14 2007 183 188
14. S Bollepalli, K Mathieson, C Bay Prevalence of risk factors for hepatitis C virus in HIV-infected and HIV/hepatitis C virus-coinfected patients Sex Transm Dis 34 2007 367 370 (Pubitemid 46816782)
15. J Fox, E Nastouli, E Thomson Increasing incidence of acute hepatitis C in individuals diagnosed with primary HIV in the United Kingdom AIDS 22 2008 666 668 (Pubitemid 351640605)
16. CC Wang, E Krantz, J Klarquist Acute hepatitis C in a contemporary US cohort: modes of acquisition and factors influencing viral clearance J Infect Dis 196 2007 1474 1482 (Pubitemid 351411983)
17. C Pasquier, L Bujan, M Daudin Intermittent detection of hepatitis C virus (HCV) in semen from men with human immunodeficiency virus type 1 (HIV-1) and HCV J Med Virol 69 2003 344 349 (Pubitemid 36158314)
18. M Danta, D Brown, S Bhagani for the HIV and Acute HCV (HAAC) group Recent epidemic of acute hepatitis C in HIV-positive men who have sex with men linked to high-risk sexual behaviours AIDS 21 2007 983 991 (Pubitemid 46684329)
19. HM Götz, G van Doornum, HG Niesters, JG den Hollander, HB Thio, ZO de A cluster of acute hepatitis C virus infection among men who have sex with men - results from contact tracing and public health implications AIDS 19 2005 969 974 (Pubitemid 40834941)
20. A Wasley, S Grytdal, K Gallagher Surveillance for acute viral hepatitis - United States, 2006 MMWR Surveill Summ 57 2008 1 24
21. GH Haydon, PJ Flegg, CS Blair, RP Brettle, SM Burns, PC Hayes The impact of chronic hepatitis C virus infection on HIV disease and progression in intravenous drug users Eur J Gastroenterol Hepatol 10 1998 485 489 (Pubitemid 28306541)
22. M Dorrucci, P Pezzotti, AN Phillips, AC Lepri, G Rezza Coinfection of hepatitis C virus with human immunodeficiency virus and progression to AIDS. Italian Seroconversion Study J Infect Dis 172 1995 1503 1508
23. G Greub, B Ledergerber, M Battegay for the Swiss HIV Cohort Study Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study Lancet 356 2000 1800 1805
24. MF Miller, C Haley, MJ Koziel, CF Rowley Impact of hepatitis C virus on immune restoration in HIV-infected patients who start highly active antiretroviral therapy: a meta-analysis Clin Infect Dis 41 2005 713 720 (Pubitemid 41170361)
25. CS Graham, LR Baden, E Yu Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis Clin Infect Dis 33 2001 562 569 (Pubitemid 32709592)
26. P Bonnard, FX Lescure, C Amiel Documented rapid course of hepatic fibrosis between two biopsies in patients coinfected by HIV and HCV despite high CD4 cell count J Viral Hepat 14 2007 806 811 (Pubitemid 47561586)
27. B Soto, A Sanchez-Quijano, L Rodrigo Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis J Hepatol 26 1997 1 5 (Pubitemid 27072597)
28. 1-producing immunoregulatory CD8+ T cells J Immunol 168 2002 2247 2254 (Pubitemid 34173033)
29. R Safadi, M Ohta, CE Alvarez Immune stimulation of hepatic fibrogenesis by CD8 cells and attenuation by transgenic interleukin-10 from hepatocytes Gastroenterology 127 2004 870 882 (Pubitemid 39208419)
30. CS Graham, M Curry, Q He Comparison of HCV-specific intrahepatic CD4+ T cells in HIV/HCV versus HCV Hepatology 40 2004 125 132 (Pubitemid 38868931)
31. JT Blackard, F Komurian-Pradel, M Perret Intrahepatic cytokine expression is downregulated during HCV/HIV co-infection J Med Virol 78 2006 202 207 (Pubitemid 43132564)
32. Y Shintani, H Fujie, H Miyoshi Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance Gastroenterology 126 2004 840 848 (Pubitemid 38298332)
33. F Blanco, P Barreiro, P Ryan Risk factors for advanced liver fibrosis in HIV-infected individuals: role of antiretroviral drugs and insulin resistance J Viral Hepat 2010 10.1111/j.1365-2893.2009.01261.x published online Jan 18.
34. Y Feng, CC Broder, PE Kennedy, EA Berger HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor Science 272 1996 872 877 (Pubitemid 26154590)
35. W Lin, EM Weinberg, AW Tai HIV increases HCV replication in a TGF-β1-dependent manner Gastroenterology 134 2008 803 811 (Pubitemid 351312737)
36. R Bruno, S Galastri, P Sacchi gp120 modulates the biology of human hepatic stellate cells: a link between HIV infection and liver fibrogenesis Gut 59 2010 513 520
37. A Balagopal, FH Philp, J Astemborski Human immunodeficiency virus-related microbial translocation and progression of hepatitis C Gastroenterology 135 2008 226 233 (Pubitemid 351899010)
38. D Ge, J Fellay, A Thompson Genetic variation in IL28B predicts hepatitis C treatment induced viral clearance Nature 461 2009 399 401
39. Y Tanaka, N Nishida, M Sugiyama Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C Nat Genet 41 2009 1105 1109
40. A Rauch, Z Kutalik, P Descombes Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study Gastroenterology 138 2010 1338 1345
41. NI Rallón, S Naggie, JM Benito Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients AIDS 24 2010 F23 F29
42. L Martin-Carbonero, V de Ledinghen, A Moreno Liver fibrosis in patients with chronic hepatitis C and persistently normal liver enzymes: influence of HIV infection J Viral Hepat 16 2009 790 795
43. S Vergara, J Macias, A Rivero The use of transient elastometry for assessing liver fibrosis in patients with HIV and hepatitis C virus coinfection Clin Infect Dis 45 2007 969 974 (Pubitemid 47580344)
44. M Nunez, C Miralles, MA Berdun Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO trial AIDS Res Hum Retroviruses 23 2007 972 982 (Pubitemid 47492337)
45. A Cargnel, E Angeli, A Mainini Open, randomized, multicentre italian trial on PEG-IFN plus ribavirin versus PEG-IFN monotherapy for chronic hepatitis C in HIV-coinfected patients on HAART Antivir Ther 10 2005 309 317 (Pubitemid 41151037)
46. FJ Torriani, M Rodriguez-Torres, JK Rockstroh Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients N Engl J Med 351 2004 438 450 (Pubitemid 38988593)
47. M Laguno, C Cifuentes, J Murillas Randomized trial comparing pegylated interferon α-2b versus pegylated interferon α-2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients Hepatology 49 2009 22 31
48. RT Chung, J Andersen, P Volberding Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons N Engl J Med 351 2004 451 459 (Pubitemid 38988594)
49. F Carrat, F Bani-Sadr, S Pol Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial JAMA 292 2004 2839 2848 (Pubitemid 39628231)
50. A Moreno, R Barcena, S Garcia-Garzon Viral kinetics and early prediction of nonresponse to peg-IFN-α-2b plus ribavirin in HCV genotypes 1/4 according to HIV serostatus J Viral Hepat 13 2006 466 473
51. G Brook, J Main, M Nelson British HIV Association guidelines for the management of coinfection with HIV-1 and hepatitis B or C virus 2010 HIV Med 11 2010 1 30
52. JG McHutchison, EJ Lawitz, ML Shiffman Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection N Engl J Med 361 2009 580 593
53. J Berenguer, J Alvarez-Pellicer, PM Martin Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus Hepatology 50 2009 407 413
54. S Dominguez, J Ghosn, MA Valantin Efficacy of early treatment of acute hepatitis C infection with pegylated interferon and ribavirin in HIV-infected patients AIDS 20 2006 1157 1161 (Pubitemid 43786104)
55. A Lafeuillade, G Hittinger, S Chadapaud Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection Lancet 357 2001 280 281 (Pubitemid 32120863)
56. S Mauss, W Valenti, J DePamphilis Risk factors for hepatic decompensation in patients with HIV/HCV coinfection and liver cirrhosis during interferon-based therapy AIDS 18 2004 F21 F25
57. F Bani-Sadr, F Carrat, E Rosenthal Spontaneous hepatic decompensation in patients coinfected with HIV and hepatitis C virus during interferon-ribavirin combination treatment Clin Infect Dis 41 2005 1806 1809 (Pubitemid 41759869)
58. SE Kellerman, DL Hanson, AD McNaghten, PL Fleming Prevalence of chronic hepatitis B and incidence of acute hepatitis B infection in human immunodeficiency virus-infected subjects J Infect Dis 188 2003 571 577 (Pubitemid 37011810)
59. LE Chapman, EE Sullivent, LA Grohskopf Recommendations for postexposure interventions to prevent infection with hepatitis B virus, hepatitis C virus, or human immunodeficiency virus, and tetanus in persons wounded during bombings and other mass-casualty events - United States, 2008: recommendations of the Centers for Disease Control and Prevention (CDC) MMWR Recomm Rep 57 2008 1 21
60. RJ Gilson, AE Hawkins, MR Beecham Interactions between HIV and hepatitis B virus in homosexual men: effects on the natural history of infection AIDS 11 1997 597 606 (Pubitemid 27135881)
61. JF Colin, D Cazals-Hatem, MA Loriot Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men Hepatology 29 1999 1306 1310 (Pubitemid 29168769)
62. CL Thio, EC Seaberg, R Skolasky Jr HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS) Lancet 360 2002 1921 1926 (Pubitemid 35472132)
63. N Brau, RK Fox, P Xiao Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: a U.S. - Canadian multicenter study J Hepatol 47 2007 527 537 (Pubitemid 47334759)
64. CJ Hoffmann, EC Seaberg, S Young Hepatitis B and long-term HIV outcomes in coinfected HAART recipients AIDS 23 2009 1881 1889
65. GJ Dore, V Soriano, J Rockstroh Frequent hepatitis B virus rebound among HIV-hepatitis B virus-coinfected patients following antiretroviral therapy interruption AIDS 24 2010 857 865
66. UH Iloeje, HI Yang, J Su, CL Jen, SL You, CJ Chen Predicting cirrhosis risk based on the level of circulating hepatitis B viral load Gastroenterology 130 2006 678 686 (Pubitemid 43374518)
67. V Soriano, M Puoti, M Peters Care of HIV patients with chronic hepatitis B: updated recommendations from the HIV-Hepatitis B Virus International Panel AIDS 22 2008 1399 1410
68. P Miailhes, P Pradat, M Chevallier Proficiency of transient elastography compared to liver biopsy for the assessment of fibrosis in HIV/HBV-coinfected patients J Viral Hepat 2010 10.1111/j.1365-2893.2010.01275.x published online Feb 23.
69. European Association for the Study of the Liver EASL clinical practice guidelines: management of chronic hepatitis B J Hepatol 50 2009 227 242
70. GJ Dore, DA Cooper, C Barrett, LE Goh, B Thakrar, M Atkins Dual efficacy of lamivudine treatment in human immunodeficiency virus/hepatitis B virus-coinfected persons in a randomized, controlled study (CAESAR). The CAESAR Coordinating Committee J Infect Dis 180 1999 607 613 (Pubitemid 29411344)
71. LM Wolters, HG Niesters, BE Hansen Development of hepatitis B virus resistance for lamivudine in chronic hepatitis B patients co-infected with the human immunodeficiency virus in a Dutch cohort J Clin Virol 24 2002 173 181
72. Benhamou Y. Three year treatment with adefovir dipivoxil in chronic hepatitis B patients with lamivudine resistant HBV and HIV cco-infection results in significant and sustained clinical improvement. 11th Conference on Retroviruses and Opportunistic Infections; Feb 8-11, 2004; San Francisco, CA, USA. Abstr 385.
73. SJ Hadziyannis, NC Tassopoulos, EJ Heathcote Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B N Engl J Med 352 2005 2673 2681 (Pubitemid 41007822)
74. MG Peters, J Andersen, P Lynch Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127 Hepatology 44 2006 1110 1206
75. G Chander, B Lau, RD Moore Hazardous alcohol use: a risk factor for non-adherence and lack of suppression in HIV infection J Acquir Immune Defic Syndr 43 2006 411 417 (Pubitemid 44737097)
76. AA Chaudhry, MS Sulkowski, G Chander, RD Moore Hazardous drinking is associated with an elevated aspartate aminotransferase to platelet ratio index in an urban HIV-infected clinical cohort HIV Med 10 2009 133 142
77. L Aranzabal, JL Casado, J Moya Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection Clin Infect Dis 40 2005 588 593 (Pubitemid 40270230)
78. JC Servoss, DW Kitch, JW Andersen, RB Reisler, RT Chung, GK Robbins Predictors of antiretroviral-related hepatotoxicity in the adult AIDS Clinical Trial Group (1989-1999) J Acquir Immune Defic Syndr 43 2006 320 323 (Pubitemid 44674012)
79. MS Sulkowski, DL Thomas, RE Chaisson, RD Moore Elevated liver enzymes following initiation of antiretroviral therapy JAMA 283 2000 2526 2527 (Pubitemid 30324193)
80. I Sanne, H Mommeja-Marin, J Hinkle Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects J Infect Dis 191 2005 825 829 (Pubitemid 40349795)
81. P Bossi, D Colin, F Bricaire, E Caumes Hypersensitivity syndrome associated with efavirenz therapy Clin Infect Dis 30 2000 227 228 (Pubitemid 30067101)
82. M Laguno, A Milinkovic, E de Lazzari Incidence and risk factors for mitochondrial toxicity in treated HIV/HCV-coinfected patients Antivir Ther 10 2005 423 429 (Pubitemid 41151020)
83. JC Shlay, G Bartsch, G Peng Long-term body composition and metabolic changes in antiretroviral naive persons randomized to protease inhibitor-, nonnucleoside reverse transcriptase inhibitor-, or protease inhibitor plus nonnucleoside reverse transcriptase inhibitor-based strategy J Acquir Immune Defic Syndr 44 2007 506 517 (Pubitemid 46594893)
84. MS Sulkowski, SH Mehta, M Torbenson Hepatic steatosis and antiretroviral drug use among adults coinfected with HIV and hepatitis C virus AIDS 19 2005 585 592 (Pubitemid 40543981)
85. M Nunez Hepatotoxicity of antiretrovirals: incidence, mechanisms and management J Hepatol 44 suppl 2006 S132 S139
86. H Kovari, B Ledergerber, M Battegay Incidence and risk factors for chronic elevation of alanine aminotransferase levels in HIV-infected persons without hepatitis b or c virus co-infection Clin Infect Dis 50 2010 502 511
87. S Sauleda, M Martorell, JI Esteban Hepatotoxicity of antiretroviral drugs in HIV HCV patients with congenital coagulopathies followed at an haemophilia unit during a decade Haemophilia 12 2006 228 236
88. M den Brinker, FW Wit, PM Wertheim-van Dillen Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection AIDS 14 2000 2895 2902 (Pubitemid 32042753)
89. MS Sulkowski, DL Thomas, SH Mehta, RE Chaisson, RD Moore Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections Hepatology 35 2002 182 189 (Pubitemid 34032559)
90. A Rivero, JA Mira, JA Pineda Liver toxicity induced by non-nucleoside reverse transcriptase inhibitors J Antimicrob Chemother 59 2007 342 346 (Pubitemid 47073440)
91. J Ena, C Amador, C Benito, V Fenoll, F Pasquau Risk and determinants of developing severe liver toxicity during therapy with nevirapine-and efavirenz-containing regimens in HIV-infected patients Int J STD AIDS 14 2003 776 781 (Pubitemid 37372234)
92. MS Sulkowski Drug-induced liver injury associated with antiretroviral therapy that includes HIV-1 protease inhibitors Clin Infect Dis 38 suppl 2 2004 S90 S97
93. MS Sulkowski, DL Thomas, RE Chaisson, RD Moore Elevated liver enzymes following initiation of antiretroviral therapy JAMA 283 2000 2526 2527 (Pubitemid 30324193)
94. MS Sulkowski Drug-induced liver injury associated with antiretroviral therapy that includes HIV-1 protease inhibitors Clin Infect Dis 38 suppl 2 2004 S90 S97
95. Viracept (nelfinavir) Prescribing information (USA) 1999 Agouron Laboratories San Diego, CA
96. Crixivan (indinavir sulfate) Prescribing information (USA) 2001 Merck Whitehouse Station, NJ
97. Reyataz (atazanavir sulfate) Prescribing information (USA) 2003 Bristol-Myers Squibb Princeton, NJ
98. Norvir (ritonavir) Prescribing information (USA) 1999 Abbott Laboratories North Chicago, IL
99. Fortovase (saquinavir) Prescribing information (USA) 1998 Roche Laboratories Nultey, NJ
100. CL Cooper, MA Parbhakar, JB Angel Hepatotoxicity associated with antiretroviral therapy containing dual versus single protease inhibitors in individuals coinfected with hepatitis C virus and human immunodeficiency virus Clin Infect Dis 34 2002 1259 1263 (Pubitemid 34450675)
101. I Maida, M Nunez, MJ Rios Severe liver disease associated with prolonged exposure to antiretroviral drugs J Acquir Immune Defic Syndr 42 2006 177 182 (Pubitemid 43884712)
102. H Kovari, B Ledergerber, U Peter Association of noncirrhotic portal hypertension in HIV-infected persons and antiretroviral therapy with didanosine: a nested case-control study Clin Infect Dis 49 2009 626 635
103. S Saifee, D Joelson, J Braude Noncirrhotic portal hypertension in patients with HIV infection Clin Gastroenterol Hepatol 6 2008 1167 1169
104. V Mallet, A Varthaman, D Lasne HIV-associated nodular regenerative hyperplasia is linked to portal obstructive venopathy and autoimmune protein S deficiency Hepatology 46 suppl 2007 576A
105. E Vispo, A Moreno, I Maida Noncirrhotic portal hypertension in HIV-infected patients: unique clinical and pathological findings AIDS 24 2010 1171 1176
106. PF Sandrine, A Sylvie, E Andre, D Abdoulaye, L Bernard, C Andre Nodular regenerative hyperplasia: a new serious antiretroviral drugs side effect? AIDS 21 2007 1498 1499 (Pubitemid 46988019)
107. TD Schiano, DP Kotler, E Ferran, MI Fiel Hepatoportal sclerosis as a cause of noncirrhotic portal hypertension in patients with HIV Am J Gastroenterol 102 2007 2536 2540 (Pubitemid 47631766)
108. V Mallet, P Blanchard, V Verkarre Nodular regenerative hyperplasia is a new cause of chronic liver disease in HIV-infected patients AIDS 21 2007 187 192 (Pubitemid 46036926)
109. N Crum-Cianflone, A Dilay, G Collins Nonalcoholic fatty liver disease among HIV-infected persons J Acquir Immune Defic Syndr 50 2009 464 473
110. CA Matteoni, ZM Younossi, T Gramlich, N Boparai, YC Liu, AJ McCullough Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity Gastroenterology 116 1999 1413 1419 (Pubitemid 29258890)
111. P Angulo GI epidemiology: nonalcoholic fatty liver disease Aliment Pharmacol Ther 25 2007 883 889
112. G Moyle, A Carr HIV-associated lipodystrophy, metabolic complications, and antiretroviral toxicities HIV Clin Trials 3 2002 89 98 (Pubitemid 34183098)
113. SW Worm, N Friis-Moller, M Bruyand High prevalence of the metabolic syndrome in HIV-infected patients: impact of different definitions of the metabolic syndrome AIDS 24 2010 427 435
114. G Guaraldi, N Squillace, C Stentarelli Nonalcoholic fatty liver disease in HIV-infected patients referred to a metabolic clinic: prevalence, characteristics, and predictors Clin Infect Dis 47 2008 250 257 (Pubitemid 351920629)
115. SS Mohammed, E Aghdassi, IE Salit HIV-positive patients with nonalcoholic fatty liver disease have a lower body mass index and are more physically active than HIV-negative patients J Acquir Immune Defic Syndr 45 2007 432 438 (Pubitemid 47057670)
116. P Ingiliz, MA Valantin, C Duvivier Liver damage underlying unexplained transaminase elevation in human immunodeficiency virus-1 mono-infected patients on antiretroviral therapy Hepatology 49 2009 436 442
117. R Trotti, B Cestaro, R Cazzola, E Ferrari, M Rondanelli Adipose tissue and cytokines Minerva Gastroenterol Dietol 47 2001 205 207
118. G Altavilla, A Caputo, M Lanfredi, C Piola, G Barbanti-Brodano, A Corallini Enhancement of chemical hepatocarcinogenesis by the HIV-1 tat gene Am J Pathol 157 2000 1081 1089
119. D Salmon-Ceron, E Rosenthal, C Lewden Emerging role of hepatocellular carcinoma among liver-related causes of deaths in HIV-infected patients: the French national Mortalité 2005 study J Hepatol 50 2009 736 745
120. M Puoti, R Bruno, V Soriano Hepatocellular carcinoma in HIV-infected patients: epidemiological features, clinical presentation and outcome AIDS 18 2004 2285 2293 (Pubitemid 39620221)
121. MV Ragni, SH Belle, K Im Survival of human immunodeficiency virus-infected liver transplant recipients J Infect Dis 188 2003 1412 1420 (Pubitemid 37523925)
122. JC Duclos-Vallee, C Feray, M Sebagh Survival and recurrence of hepatitis C after liver transplantation in patients coinfected with human immunodeficiency virus and hepatitis C virus Hepatology 47 2008 407 417 (Pubitemid 351280708)
123. ME de Vera, I Dvorchik, K Tom Survival of liver transplant patients coinfected with HIV and HCV is adversely impacted by recurrent hepatitis C Am J Transplant 6 2006 2983 2993
124. J O'Grady, C Taylor, G Brook Guidelines for liver transplantation in patients with HIV infection HIV Med 6 suppl 2 2005 149 153 (Pubitemid 41038590)
125. AL Mindikoglu, A Regev, LS Magder Impact of human immunodeficiency virus on survival after liver transplantation: analysis of United Network for Organ Sharing database Transplantation 85 2008 359 368 (Pubitemid 351322759)
126. Terrault N, Barin B, Schiano TD, et al. Survival and risk of severe hepatitis C Virus (HCV) recurrence in liver transplant recipients co-infected with human immunodeficiency virus and HCV. 60th Annual Meeting of the American Association for the Study of Liver Diseases; Boston, MA, USA; Oct 30-Nov 3, 2009. Abstr 195.
127. Joshi D, Aluvihare V, Belgaumkar A, et al. Liver transplantation for HIV: analysis of outcomes suggest HIV.HCV co-infected patients have prohibitively poor survival at 5 years. 59th Annual Meeting of the American Association for the Study of Liver Diseases; San Francisco, CA, USA; Oct 31-Nov 4, 2008. Abstr 6.
128. NA Terrault, JT Carter, L Carlson, ME Roland, PG Stock Outcome of patients with hepatitis B virus and human immunodeficiency virus infections referred for liver transplantation Liver Transpl 12 2006 801 807
129. L Tricot, E Teicher, G Peytavin Safety and efficacy of raltegravir in HIV-infected transplant patients cotreated with immunosuppressive drugs Am J Transplant 9 2009 1946 1952